Ronde-cel achieves 91% response rate in pivotal large B-cell lymphoma trial ahead of ASH 2026 – Lyell
Lyell Immunopharma will present updated data for rondecabtagene autoleucel (ronde-cel), its investigational dual-targeting CD19/CD20 CAR T-cell therapy, in relapsed or refractory large B-cell lymphoma (LBCL). The data will… read more.
